Agonists and antagonists for P2 receptors

Novartis Foundation Symposium

Volumn 276, Issue , 2006, Pages 58-68

  Jacobson, Kenneth A ^a   Costanzi, Stefano ^a   Joshi, Bhalchandra V ^a   Besada, Pedro ^a   Dae, Hong Shin ^a   Ko, Hyojin ^a   Ivanov, Andrei A ^a   Mamedova, Liaman ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; NUCLEOTIDE; PURINE P2 RECEPTOR;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; METABOLISM; PROTEIN CONFORMATION; REVIEW;

ANIMALS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NUCLEOTIDES; PROTEIN CONFORMATION; RECEPTORS, PURINERGIC P2;

EID: 33747431924     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (47)

1. 7 receptor antagonists. Bioorg Med Chem Lett 13:4047-4050
2. Besada P, Mamedova L, Thomas CJ, Costanzi S, Jacobson KA 2005 Design and synthesis of new bicyclic diketopiperazines as scaffolds for receptor probes of structurally diverse functionality. Org Biomol Chem 3:2016-2025
3. 5 receptor. Mol Pharmacol 63:1407-1416
4. Bianchi BR, Lynch KJ, Touma E et al 1999 Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol 376:127-138
5. 1 receptor. Biochem Pharmacol 68:1995-2002
6. 7 receptor antagonists: probing multiple sites for linking and dimerization. Bioconj Chem 13:1100-1111
7. 13 receptors by conformational constraint of an ADP analogue. J Pharm Exp Therap 311:1038-1043
8. Costanzi S, Mamedova L, Gao ZG, Jacobson KA 2004 Architecture of P2Y nucleotide receptors: Structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem 47:5393-5404
9. 6 receptor: Molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. J Med Chem 48:8108-8111
10. Coutinho-Silva R, Stahl L, Cheung KK et al 2005 P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am J Physiol Gastrointest Liver Physiol 288:G1024-1035
11. 12 platelet receptor. Haematologica 87S1:22
12. Dunn PM, Kim HS, Jacobson KA, Burnstock G 2004 Northern ring conformation of methanocarba-adenosine 5′-triphosphate required for activation of P2X receptors. Drug Devel Res 61:227-232
13. 2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J Biol Chem 270:4185-4188
14. th National Meeting of the American Chemical Soc, San Diego, CA, March 11, 2005, Abstract MEDI 80
15. Garcia-Guzman M, Soto F, Gomez-Hernandez JM, Lund PE, Stuhmer W 1997 Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue. Mol Pharmacol 51:109-118
16. 1/6 chimeric receptors. Biochem Pharmacol 68:2075-2086
17. 1 receptors. Brit J Pharmacol, in press
18. 2T receptor: A novel approach to antithrombotic therapy. J Med Chem 42: 213-220
19. Jacobson KA, Jarvis MF, Williams M 2002 Purine and pyrimidine (P2) receptors as drug targets. J Med Chem 45:4057-4093
20. Jacobson KA, Costanzi S, Ohno M et al 2004 Molecular recognition at purine and pyrimidine nucleotide (P2) receptors. Current Topics Med Chem 4:805-819
21. 1 antagonist. 15:3292-3295
22. Jarvis MF, Burgard EC, McGaraughty S 2002 et al A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci USA 99:17179-17184
23. 6 receptors by N-linked glycosylation: identification of a novel alpha beta-methylene ATP-sensitive phenotype. Mol Pharmacol 65:979-985
24. Khakh BS, Burnstock G, Kennedy C et al 2001 International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 53:107-118
25. 6 receptors. J Med Chem 45:208-218
26. 6 nucleotide receptor activates PKC to protect 1321N1 astrocytoma cells against tumor necrosis factor-induced apoptosis. Cell Mol Neurobiol 23:401-418
27. 1 receptor antagonists. J Med Chem 46:4974-4987
28. 13 receptor. Biochem Pharmacol 70:266-274
29. Lazarowski ER, Watt WC, Stutts MJ, Brown HA, Boucher RC, Harden TK 1996 Enzymatic synthesis of UTPγS, a potent hydrolysis resistant agonist of P2U-purinoreceptors. Br J Pharmacol 117:203-209
30. Malmsjö M, Adner M, Harden TK, Pendergast W, Edvinsson L, Erlinge D 2000 The stable pyrimidines UDPβS and UTPγS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery. Br J Pharmacol 131:51-56
31. 6 nucleotide receptors. Biochem Pharmacol 67:1763-1770
32. th ACS National meeting, Abstracts, Division of Medicinal Chemistry, 12
33. 7 receptor antagonists. Bioorg Med Chem Lett 15:435-438
34. 1 receptor. Biochemistry 38:3498-3507
35. Moro S, Jacobson KA 2002 Molecular modeling as a tool to investigate molecular recognition in P2Y receptors. Curr Pharmaceut Design 8:99-110
36. Ohno M, Costanzi S, Kim HS et al 2004 Nucleotide analogues containing 2-oxabicyclo[2.2.1]heptane and L-α-threofuranosyl ring systems: Interactions with P2Y receptors. Bioorganic Med Chem 12:5619-5630
37. Rettinger J, Braun K, Hochmann H et al 2005 Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. Neuropharmacology 48:461-468
38. 7 receptor. Bioorg Med Chem Lett 14:5709-5712
39. 12). Bioorg Med Chem Lett 11:1805-1808
40. 2/3 receptors. Br J Pharmacol 140:1027-1034
41. Shaver SR, Rideout JL, Pendergast W 2005 Structure-activity relationships of dinucleotides: potent and selective agonists of P2Y receptors. Purinergic Signalling 1:183-191
42. 12 antagonists. Semin Thromb Hemost 31:195-204
43. 1 receptor with a high affinity radiolabeled antagonist. Mol Pharmacol 62:1249-1257
44. 1. Mol Pharmacol 62:957-966
45. 2+ ions. Br J Pharmacol 140:1177-1186
46. 2 receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther 302:871-880
47. Yitzhaki S, Shneyvais V, Jacobson KA, Shainberg A 2005 Involvement of uracil nucleotides in protection of cardiomyocytes from hypoxic stress. Biochem Pharmacol 69:1215-1223